Updates to the Standards of Medical Care in Diabetes 2022 by ADA
Important updates to the Standards of Medical Care in Diabetes – 2022 (Standards of Care), in annotations as the Living Standards of Care, have been published by the ADA. These include new information on finerenone in T2DM and CKD; SGLT2 inhibitors in T2DM and their effect on HF and kidney outcomes; and on calculating eGFR and inclusion of race for diagnosis of kidney disease. Updates were added to section 10 and 11 in the Standards of Care.
“This is the fifth year that we are able to update the Standards of Care after it has been published through our Living Standards of Care updates, making it possible to give diabetes care providers the most important information and the latest evidence relevant to their practice,” said Dr. Robert Gabbay, chief scientific and medical officer for the ADA.